• 7 results in Exploration of Targeted Anti-tumor Therapy
    Sort by
    Latest
    Open Access
    Review
    Interface between obesity with dysfunctional metabolism and inflammation, and the triple-negative breast cancer in African American women
    Obesity has dramatically increased over the past fifty years. In the last decade, it has been noted that augmented body mass, metabolic abnormalities, and the relevant “obese” [...] Read more.
    Katarzyna Rygiel
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:602–616
    DOI: https://doi.org/10.37349/etat.2021.00066
    This article belongs to the special issue Endocrine Resistant Breast Cancer
    View:1514
    Download:55
    Open Access
    Original Article
    The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type
    Aim: Bromodomain and extra-terminal domain (BET) proteins are epigenetic readers that play a fundamental role in transcription regulation. Preclinical and early clinical evidence sustain BET targ [...] Read more.
    Chiara Tarantelli ... Francesco Bertoni
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:586–601
    DOI: https://doi.org/10.37349/etat.2021.00065
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:2617
    Download:97
    Open Access
    Original Article
    Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates
    Aim: Direct analytical comparison of two major drug-linkers in the antibody-drug conjugate (ADC) field was conducted. Methods: Four different analytical methods [AlogP calculation, reverse phase (RP) high-performance liquid chrom [...] Read more.
    Tomohiro Fujii ... Yutaka Matsuda
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:576–585
    DOI: https://doi.org/10.37349/etat.2021.00064
    This article belongs to the special issue Antibody-Drug Conjugates
    View:2578
    Download:157
    Open Access
    Original Article
    Alterations in the Ca2+ toolkit in oesophageal adenocarcinoma
    Aim: To investigate alterations in transcription of genes, encoding Ca2+ toolkit proteins, in oesophageal adenocarcinoma (OAC) and to assess associations between gene expression, tumor  [...] Read more.
    Alana L. Cutliffe ... John J. Mackrill
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:543–575
    DOI: https://doi.org/10.37349/etat.2021.00063
    This article belongs to the special issue Calcium Signaling Apparatus in Cancers
    View:2035
    Download:51
    Open Access
    Review
    Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
    The dismal prognosis of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) prompted recent advances in the field of therapeutic approaches beyond cytotoxic cancer therapy. In r [...] Read more.
    Stefano Cavalieri ... Laura D. Locati
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:522–542
    DOI: https://doi.org/10.37349/etat.2021.00062
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:2312
    Download:97
    Open Access
    Review
    The clinical advances of proteolysis targeting chimeras in oncology
    Proteolysis targeting chimeras (PROTACs) are a class of small molecules designed to target proteins for degradation. Their novel and unique modes of action provide PROTACs with the potential for the [...] Read more.
    Hao Xie ... Jason B. Fleming
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:511–521
    DOI: https://doi.org/10.37349/etat.2021.00061
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:4255
    Download:214
    Open Access
    Review
    Proteolysis-targeting chimeras and their implications in breast cancer
    Breast cancer (BC) is a highly heterogeneous neoplasm of the mammary tissue, causing the deaths of a large number of women worldwide. Nearly 70% and 20% of BC cases are estro [...] Read more.
    Angeles C. Tecalco-Cruz ... Alberto Rojas-Ochoa
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:496–510
    DOI: https://doi.org/10.37349/etat.2021.00060
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:2356
    Download:88